Top Markets
Coin of the day
Epigenomics AG Epigenomics AG

Epigenomics AG

ECX
Rank in Stocks #38936
Founded in 1998 and headquartered in Berlin, Germany, Epigenomics AG is a... Founded in 1998 and headquartered in Berlin, Germany, Epigenomics AG is a molecular diagnostics company dedicated to the early detection of cancer through liquid biopsy methods. Its primary offering, Epi proColon, is a blood-based assay specifically developed for the early identification of colorectal cancer, distributed across the United States, Europe, and China. The company's portfolio further encompasses a blood test for hepatocellular carcinoma and Epi BiSKit, a pre-analytical solution providing reagents essential for preparing bisulfite-converted DNA. Epigenomics' research and development initiatives are focused on pinpointing relevant biomarkers in human tissue and subsequently creating and securing patents for associated in vitro diagnostic blood tests.
Share Price
$0.83030862
Last synced: 2024-06-27
Market Cap
$726.64K
Change (1 day)
-1.35%
Change (1 year)
0.00%
Country
DE
Trade Epigenomics AG (ECX)

Category

Earnings for Epigenomics AG (ECX)
Earnings in 2026 TTM: 0
According to Epigenomics AG latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Epigenomics AG from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$7.61B -
US
$4.76B -
US
- -
CN
$-252.70M -
US
$1.42B -
US